---
schema_version: "secwatch.filing_event.v1"
accession: "0001658247-25-000022"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:55:39.669719+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics CMO Dana Pizzuti steps down; transitions to advisor roles with $577k severance

## Summary
- Dr. Dana Pizzuti steps down as CMO effective Dec 31, 2025; serves as Strategic Regulatory and Development Advisor through Mar 31, 2026.
- Severance of $577,000 (12 months base salary) plus COBRA reimbursement and up to $15,000 in legal fees.
- Advisor engagement from Apr 1, 2026 to Mar 30, 2028; $600/hour, up to 20 hours/month; equity continues to vest.
- Transition duties include EU MAA approval for paltusotine (acromegaly), Brazil submission, and SKK Japanese application.

## SEC filing metadata
- accession: 0001658247-25-000022
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000165824725000022/0001658247-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000165824725000022/crnx-20251216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001658247-25-000022
- JSON: https://secwatch.observer/filing/0001658247-25-000022.json
- Plain text: https://secwatch.observer/filing/0001658247-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.